Margins matter. The more Eli Lilly (NYSE: LLY) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Eli Lilly's competitive position could be.
Here's the current margin snapshot for Eli Lilly and some of its sector and industry peers and direct competitors.
|
Company |
TTM Gross Margin |
TTM Operating Margin |
TTM Net Margin |
|---|---|---|---|
|
Eli Lilly |
80.0% |
28.8% |
21.1% |
|
AstraZeneca (NYSE: AZN) |
81.7% |
39.3% |
23.8% |
|
sanofi-aventis (NYSE: SNY) |
73.1% |
23.4% |
19.5% |
|
GlaxoSmithKline (NYSE: GSK) |
74.5% |
26.3% |
13.5% |
Source: Capital IQ, a division of Standard & Poor's. TTM = trailing 12 months.
Unfortunately, that table doesn't tell us much about where Eli Lilly has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter. You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.
Here's the margin picture for Eli Lilly over the past few years.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FY= fiscal year. TTM = trailing 12 months.
(Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them.)
Here's how the stats break down:
- Over the past five years, gross margin peaked at 80.6% and averaged 78%. Operating margin peaked at 29.2% and averaged 26.7%. Net margin peaked at 19.8% and averaged 11.2%.
- TTM gross margin is 80%, 200 basis points better than the five-year average. TTM operating margin is 28.8%, 210 basis points better than the five-year average. TTM net margin is 21.1%, 990 basis points better than the five-year average.
With recent TTM margins all exceeding historical averages, Eli Lilly looks like it is doing fine.
If you take the time to read past the headlines and crack a filing now and then, you're probably ahead of 95% of the market's individual investors. To stay ahead, learn more about how I use analysis like this to help me uncover the best returns in the stock market. Got an opinion on the margins at Eli Lilly? Let us know in the comments below.
- Add Eli Lilly to My Watchlist.
- Add AstraZeneca to My Watchlist.
- Add sanofi-aventis to My Watchlist.
- Add GlaxoSmithKline to My Watchlist.
